Volume 82 | ESPE2014 | Next issue

ESPE 2014

Dublin, Ireland
18 Sep 2014 - 20 Sep 2014

Card image cap
Dublin, Ireland; 18-20 September 2014. Further information

Poster Presentations

Growth (2)

Final Height and Safety Outcomes in GH-Treated Children with Short Stature Homeobox-Containing Gene (SHOX) Deficiency: Experience From a Large, Multinational, and Prospective Observational Study
aEli Lilly and Company, Windlesham, Surrey, UK; bSydney Children’s Hospital,, Randwick, New South Wales, Australia; cEli Lilly and Company, Indianapolis, Indiana, USA; dThomas Jefferson University, Philadelphia, Pennsylvania, USA; eUniversity of Montreal and CHU Ste-Justine, Montreal, Quebec, Canada; fErasmus Medical Centre Sophia, Rotterdam, The Netherlands; gUniversity of Giessen, Giessen, Germany
hrp0082p1-d3-160
Safety and Effectiveness of Increlex[reg] Therapy in Children Enrolled in the Increlex[reg] Growth Forum Database in Europe: 4 Years Interim Results
aHôpital Necker Enfants Malades, AP-HP, Université Paris Descartes, Paris, France; bChildren’s Hospital, University of Bonn, Bonn, Germany; cFaculty of Health Sciences, Linköping University, Linköping, Sweden; dIPSEN Pharma, Boulogne Billancourt, France
hrp0082p1-d3-161
Infliximab Improves Growth in Paediatric Crohn[apos]s disease Only if Commenced Early in Puberty or Prior to the Onset of Puberty
aDepartment of Paediatric Endocrinology, Alder Hey Children’s Hospital, Liverpool, UK; bLiverpool Medical University, Liverpool, UK; cDepartment of Paediatric Gastroenterology, Alder Hey Children’s Hospital, Liverpool, UK
hrp0082p1-d3-162
Six Months Follow-Up Pharmacokinetics and Pharmacodynamics Profile of Once-weekly, CTP-modified Human GH (MOD-4023;): phase 2 Dose Finding Study in Children with GHD Deficiency
aPROLOR Biotech, Nes Ziona, Israel; bKaplan Medical Center, Rechovot, Israel; c2nd Children City Clinic, Minsk, Belarus; dUkrainian Children Specialized Clinical Hospital, Kyev, Ukraine; eBashkir State Medical University, Ufa, Russia; fUMHAT ‘Sv. Marina’, Varna, Bulgaria; gSt. Petersburg State Pediatric Medical Academy, St Petersburg, Russia
hrp0082p1-d3-163
Validating Genetic Markers of Response to Recombinant Human GH in Children with GH Deficiency or Turner Syndrome: Results From the PREDICT Validation Study
aDépartement de Pédiatrie, Université Claude Bernard, Lyon, France; bManchester Academic Health Sciences Centre, Royal Manchester Children’s Hospital, Manchester, UK; cQuartz Bio, Geneva, Switzerland
hrp0082p1-d3-165
Aromatase Inhibitors in Girls: Anastrazole Combined to an LHRH Analogue is a Safe and Effective Strategy in Girls with Early or Precocious Puberty with Compromised Growth Potential
aDivision of Pediatric Endocrinology, 3rd Department of Pediatrics, Attikon Univeristy Hospital, Athens, Greece; bDivision of Pediatric Endocrinology, Athens Medical Center, Athens, Greece
hrp0082p1-d3-167
Abstract unavailable
hrp0082p1-d3-168
Recombinant Human GH Therapy Allows to Reach a Normal Final Adult Height in Coeliac Children with GH Deficiency due to Hypophysistis
aDepartment of Medical and Surgical Sciences of the Mother, Children and Adults, University of Modena and Reggio Emilia, Modena, Italy; bDepartment of Clinical and Experimental Medicine and Surgery 2, Chair of Endocrinology, Second University of Naples, Naples, Italy
hrp0082p1-d3-169
The ZOMATRIP Study: 4 Year Combination Therapy of GH and GnRHa in Girls with a Short Predicted Adult Height During Early Puberty: Interim Results at the End of the Treatment Phase
aBSGPE, Brussels, Belgium; bUniversity Hospital Antwerp, Edegem, Belgium; cHopital Universitaire des Enfants Reine Fabiola, Brussels, Belgium; dUniversity Hospital Ghent, Ghent, Belgium; eJessa Hospital, Hasselt, Belgium; fUniversity Hospital Liège, Liège, Belgium; gUniversity Hospital Brussels, Brussels, Belgium
hrp0082p1-d3-170
Safety and Efficacy Results of a 6 Month, Randomized, Multi-Center Trial of a Novel Long-Acting rhGH (VRS-317) in Naive to Treatment, Pre-Pubertal Children with GH Deficiency
aVersartis, Inc, Redwood City, California, USA; bChildren’s Mercy Hospital, Kansas City, Missouri, USA; cSierra Medical Research, Clovis, CA, USA; dSwedish Pedaitric Specialty Clinics, Seattle, Washington, USA; eUniversity of Minnesota, Minneapolis, Minnesota, USA; fAmplatz Children’s Hospital, Minneapolis, Minnesota, USA; gCleveland Clinic, Cleveland, Ohio, USA
hrp0082p1-d3-171
Three-Years Height Outcome During rh-GH Therapy in Subjects with Achondroplasia and Hypochondroplasia
aMaternal and Infant Department, St Chiara University Hospital of Pisa, Pisa, Italy; bPediatric Unit, ASL2 Lucca Hospital, Lucca, Italy; cEpidemiology Unit, Department of Experimental Pathology M.B.I.E., University of Pisa, Pisa, Italy
hrp0082p1-d3-172